HELP logo

Helus Pharma Inc. (HELP)

$7.20

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on HELP

Market cap

$574615202

EPS

-2.98

P/E ratio

--

Price to sales

--

Dividend yield

--

Beta

0.649554

Price on HELP

Previous close

$7.67

Today's open

$7.81

Day's range

$7.03 - $8.07

52 week range

$3.76 - $15.15

Profile about HELP

CEO

Michael Halstead

Employees

100

Headquarters

Toronto, Ontario

Exchange

NASDAQ Global Market

Shares outstanding

79807667

Issue type

Common Stock

HELP industries and sectors

Healthcare

Biotechnology & Life Sciences

News on HELP

Helus Pharma's psychedelic depression drug succeeds in late-stage study

Helus Pharma said ​on Monday its ‌experimental psychedelic drug showed statistically significant improvement ​in depression symptoms ​compared with placebo in ⁠a late-stage ​trial in patients with ​major depressive disorder.

news source

Reuters • Nov 16, 2026

news preview

Helus Pharma Reports Second Quarter Fiscal 2027 Financial Results and Recent Business Highlights

Appointed Michael Halstead as Chief Executive Officer to lead Helus Pharma through late-stage development and commercialization      Completed enrollment in the Phase 3 APPROACH pivotal study of HLP003 in major depressive disorder (“MDD”); topline data remains on track for Q4 2026 1 , 2        Announced design of upcoming HLP004 Phase 2 monotherapy study in generalized anxiety disorder (“GAD”); expected to initiate in Q1 2027 1 ,2     Appointed Dr. Suresh Durgam, former Executive Vice President and Chief Medical Officer of Intra-Cellular Therapies, Inc. to the Company's Board of Directors     Appointed Helus Pharma board member, Mark Lawson, independent Chair of the Board of Directors This news release constitutes a “designated news release” for the purpose of the Company's prospectus supplement dated December 30, 2025, to its short form base shelf prospectus dated September 17, 2025, as amended on December 19, 2025. NEW YORK and TORONTO, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Helus Pharma Inc. (Nasdaq: HELP) (Cboe CA: HELP) (the “Company” or “Helus Pharma”), a clinical-stage pharmaceutical company committed to improving the treatment landscape in mental health through the development and commercialization of novel serotonergic agonists (“NSAs”), today reported recent business highlights and financial results for its fiscal quarter ended September 30, 2026.

news source

GlobeNewsWire • Nov 16, 2026

news preview

Helus Pharma Touts Positive Data for Depression Drug

Helus Pharma Inc. (NASDAQ:HELP) reported topline results from its pivotal Phase 3 APPROACH trial, showing its novel serotonergic agonist HLP003 rapidly and durably reduced symptoms in adults with major depressive disorder.

news source

Benzinga • Nov 16, 2026

news preview

Helus Pharma Announces Positive Topline Results from Phase 3 APPROACH Study evaluating HLP003 as Adjunctive Treatment in Major Depressive Disorder

HLP003 achieved statistically significant and clinically meaningful results in the primary and key secondary endpoints starting as early as Day 2 and maintained at all time points -7.6 point placebo-adjusted change from baseline at Week 6 for the primary endpoint on the Montgomery-Asberg Depression Rating Scale (“MADRS”) (p< 0.0001) Durable effect maintained through Week 12 (key secondary endpoint) with a -7.0 point placebo-adjusted change from baseline on the MADRS (p< 0.0001) Robust and statistically significant response and remission rates starting as early as Day 2 and maintained at all time points HLP003 was generally well-tolerated This news release constitutes a “designated news release” for the purpose of the Company's prospectus supplement dated December 30, 2025, to its short form base shelf prospectus dated September 17, 2025, as amended on December 19, 2025. Company to host webcast at 8:00 AM ET today NEW YORK and TORONTO,, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Helus Pharma Inc. (Nasdaq: HELP) (Cboe CA: HELP) (“Helus Pharma” or the “Company”), a  clinical-stage pharmaceutical company committed to improving the treatment landscape in mental health conditions through the development and commercialization of novel serotonergic agonists (“NSAs”), today announced positive topline results from APPROACH, its Phase 3 pivotal study evaluating HLP003 (deuterated psilocin), as an adjunctive treatment for adults with major depressive disorder (“MDD”).

news source

GlobeNewsWire • Nov 16, 2026

news preview

Helus Pharma to Present Topline Results from Phase 3 APPROACH Study Evaluating HLP003 as Adjunctive Treatment in Major Depressive Disorder on November 16, 2026

Company to host webcast at 8:00 a.m. EDT on Monday, November 16, 2026 Company to host webcast at 8:00 a.m. EDT on Monday, November 16, 2026

news source

GlobeNewsWire • Nov 15, 2026

news preview

Cybin Expects Key Phase III Depression Trial Results This Quarter

Helus Pharma expects results from the first Phase III trial of its experimental adjunctive treatment for major depressive disorder later this quarter, CEO Michael Halstead said at the Guggenheim Healthcare Innovation Conference.

news source

MarketBeat • Nov 10, 2026

news preview

Helus Pharma to Participate in the Guggenheim Healthcare Innovation Conference

CEO Michael Halstead to participate in a fireside chat on November 9, 2026 at 3:00 p.m. EDT CEO Michael Halstead to participate in a fireside chat on November 9, 2026 at 3:00 p.m. EDT

news source

GlobeNewsWire • Nov 3, 2026

news preview

Helus Pharma Announces Co-Founders' Transition from Executive Leadership as Company Advances Toward Next Stage of Development

Co-founders to step down from executive roles and continue to serve on the Board of Directors Helus Pharma board member, Mark Lawson, appointed as new independent Chair of the Board of Directors, effective immediately This news release constitutes a “designated news release” for the purpose of the Company's prospectus supplement dated December 30, 2025, to its short form base shelf prospectus dated September 17, 2025, as amended on December 19, 2025. NEW YORK and TORONTO, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Helus Pharma Inc. (Nasdaq: HELP) (Cboe CA: HELP) (the “Company” or “Helus Pharma”), a clinical-stage pharmaceutical company committed to improving the treatment landscape in mental health through the development of novel serotonergic agonists (“NSAs”), today announced that co-founders Eric So and Paul Glavine have stepped down from their respective executive and consulting roles while continuing to serve as members of Helus Pharma's Board of Directors.

news source

GlobeNewsWire • Oct 27, 2026

news preview

Cybin Eyes Q4 Phase III Depression Data as Anxiety Program Advances

Cybin NASDAQ: HELP outlined plans for two late-stage mental health programs, with top-line data from its Phase III APPROACH study of HLP003 in major depressive disorder expected later in the fourth quarter of 2026.

news source

MarketBeat • Oct 21, 2026

news preview

Helus Pharma Inc. (HELP) Discusses Clinical Pipeline and Phase 3 Strategies for Novel Serotonergic Agonists in Mental Health Transcript

Helus Pharma Inc. (HELP) Discusses Clinical Pipeline and Phase 3 Strategies for Novel Serotonergic Agonists in Mental Health Transcript

news source

Seeking Alpha • Oct 21, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Helus Pharma Inc.

Open an M1 investment account to buy and sell Helus Pharma Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in HELP on M1